These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12499888

  • 1. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus.
    Fridell JA, Jain A, Reyes J, Biederman R, Green M, Sindhi R, Mazariegos GV.
    Transplantation; 2002 Dec 27; 74(12):1721-4. PubMed ID: 12499888
    [Abstract] [Full Text] [Related]

  • 2. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 3. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 4. Pediatric liver transplantation. A single center experience spanning 20 years.
    Jain A, Mazariegos G, Kashyap R, Kosmach-Park B, Starzl TE, Fung J, Reyes J.
    Transplantation; 2002 Mar 27; 73(6):941-7. PubMed ID: 11923697
    [Abstract] [Full Text] [Related]

  • 5. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
    Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, Fung J.
    Ann Surg; 1999 Sep 27; 230(3):441-8; discussion 448-9. PubMed ID: 10493490
    [Abstract] [Full Text] [Related]

  • 6. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 7. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J.
    Transplantation; 2003 Apr 15; 75(7):1020-5. PubMed ID: 12698091
    [Abstract] [Full Text] [Related]

  • 8. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 9. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul 15; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 10. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 11. Causes of late mortality in pediatric liver transplant recipients.
    Sudan DL, Shaw BW, Langnas AN.
    Ann Surg; 1998 Feb 15; 227(2):289-95. PubMed ID: 9488529
    [Abstract] [Full Text] [Related]

  • 12. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.
    Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, Fung J, Reyes J.
    Transplantation; 2000 Aug 27; 70(4):617-25. PubMed ID: 10972220
    [Abstract] [Full Text] [Related]

  • 13. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
    Eshraghian A, Imanieh MH, Dehghani SM, Nikeghbalian S, Shamsaeefar A, Barshans F, Kazemi K, Geramizadeh B, Malek-Hosseini SA.
    World J Gastroenterol; 2017 Feb 21; 23(7):1224-1232. PubMed ID: 28275302
    [Abstract] [Full Text] [Related]

  • 14. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z, Jiang L, Zhou T, Shen C, Chen Q, Xia Q.
    Zhonghua Er Ke Za Zhi; 2014 Aug 21; 52(8):579-82. PubMed ID: 25224233
    [Abstract] [Full Text] [Related]

  • 15. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 16. Pediatric renal transplantation under tacrolimus-based immunosuppression.
    Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Gilboa N, Gritsch HA, Irish W, McCauley J, Fung JJ, Hakala TR, Simmons RL, Starzl TE.
    Transplantation; 1999 Jan 27; 67(2):299-303. PubMed ID: 10075598
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun 27; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 18. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 19. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.
    Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, Markmann JF, Drazan KE, Holt C, Imagawa D, Goldstein LI, Martin P, Busuttil RW.
    Ann Surg; 1999 Jun 27; 229(6):824-31; discussion 831-3. PubMed ID: 10363896
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.